CAPTEM vs FOLFIRI as second-line treatment for mCRC patients

Bookmark and Share
Published: 15 Jul 2019
Views: 559
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy

Dr Filippo Pietrantonio speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about a phase II trial comparing CAPTEM versus FOLFIRI as a second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.

The aim of the study was to demonstrate a superiority of CAMPTEM in terms of progression-free survival (PFS) over FOLFIRI. Dr Pietrantonio reports that the primary endpoint was not met, however CAPTEM was shown to have similar PFS, overall survival, overall response rate and disease control rate (DCR) with a more favourable toxicity profile, compliance and quality of life.

Dr Pietrantonio explains that the next steps would be phase III studies ideally restricted to MGMT-negative population, due to patients with MGMT immunohistochemistry receiving CAPTEM achieving a significantly worse outcome in terms of both PFS and DCR.